All Oncology News

STRIDE plus lenvatinib and TACE significantly improved PFS vs TACE alone in patients with unresectable embolization-eligible HCC.

A small clinical trial led by Dana-Farber Cancer Institute builds on Salk Institute’s foundational research on vitamin D receptor and tumor microenvironment

The phase 3 HARMONi-6 showed an overall survival benefit with ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy in squamous NSCLC.

Perioperative apalutamide plus ADT improved metastasis-free survival and pathologic responses in high-risk localized prostate cancer.

Abemaciclib markedly improved PFS vs placebo in patients with advanced dedifferentiated liposarcoma.

Analyses from the evERA trial showed PFS2 and chemotherapy-free survival gains with giredestrant plus everolimus in ER+ breast cancer subgroups.

CIRCULATE provides the first prospective randomized evidence in support of a ctDNA-guided treatment escalation strategy in pMMR/MSS stage II colon cancer.

DVRd maintained efficacy benefits over VRd in transplant-ineligible, newly diagnosed multiple myeloma.

Encorafenib plus cetuximab and FOLFIRI improved PFS vs chemotherapy alone in first-line BRAF V600E–mutant metastatic colorectal cancer.

Tafasitamab plus lenalidomide and R-CHOP showed significant PFS improvements compared with R-CHOP alone in diffuse large B-cell lymphoma.

At the 2026 ASCO Annual Meeting, 3.5-year follow-up findings from the phase 3 EV-302/KEYNOTE-A39 study have been presented.

Adjuvant selpercatinib cut recurrence or death risk by 83% vs placebo in stage IB-IIIA RET fusion–positive NSCLC in LIBRETTO-432.

In the phase 3 RASolute 302 trial, daraxonrasib nearly doubled OS vs chemotherapy in previously treated metastatic PDAC, cutting the risk of death by 60%.

Ultra-low-dose nivolumab plus oral metronomic chemotherapy cut the risk of death by 43% versus paclitaxel-carboplatin in first-line platinum-sensitive recurrent or metastatic HNSCC.

A prespecified subgroup analysis of the phase 3 lidERA trial showed an iDFS benefit with adjuvant giredestrant over SOC endocrine therapy in this population.

Bezuclastinib plus sunitinib decreased the risk of progression or death by 50% compared with sunitinib monotherapy in GIST.

The B7-H4-directed ADC puxitatug samrotecan elicited responses in approximately half of patients with B7-H4-expressing recurrent or progressive endometrial cancer.

Seven-year follow-up from the CROWN trial has set a tall benchmark for the agents that followed it on the podium at the 2026 ASCO Annual Meeting in oncogene driven NSCLC.

Roughly two-thirds of high-risk patients had low Prosigna scores and could safely omit adjuvant chemotherapy without compromising 5-year IBCFS.

LY4052031 demonstrated promising clinical activity after disease progression on enfortumab vedotin in metastatic urothelial carcinoma.

Adjuvant durvalumab plus tremelimumab significantly improved DFS vs active monitoring in both high- and intermediate-risk resected RCC.

Mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed or refractory multiple myeloma.

David Dinh Tran, MD, PhD, discusses the use of LITT followed by pembrolizumab in patients with recurrent high-grade astrocytoma.

Relacorilant plus nab-paclitaxel displayed OS benefit irrespective of prior taxane exposure or taxane-free interval in platinum-resistant ovarian cancer.

Results from the phase 3 MajesTEC-9 trial show superior PFS, OS, and ORR outcomes with teclistamab monotherapy in pretreated relapsed/refractory myeloma.

The phase 3 WU-KONG28 data showed that first-line sunvozertinib improved PFS and ORR vs chemotherapy in EGFR exon 20–mutant NSCLC.

Extended follow-up data from NRG-GY018 show a sustained OS benefit with pembrolizumab plus chemotherapy regardless of MMR status or post-study ICI therapy.

Final analysis of DREAMM-9 shows promising efficacy data and an optimal dosing schedule for BVRd in transplant-ineligible newly diagnosed multiple myeloma.

Chiauranib plus weekly paclitaxel cut the risk of progression or death by 57% vs placebo plus paclitaxel in platinum-resistant or refractory ovarian cancer.

The combination cut the risk of progression or death by 65% in the first phase 3 trial of an ADC plus pembrolizumab in this setting.